Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Solid Tumor Malignancy Clinical Trial

Official title:
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03822117
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 2
Start date	October 17, 2019
Completion date	March 29, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05177276` - Selinexor Combination Ph 1 Study	Phase 1/Phase 2
Completed	`NCT00647764` - Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas	Phase 1
Recruiting	`NCT05164016` - Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
Recruiting	`NCT05768269` - A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Completed	`NCT04847050` - A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy	Phase 2